Article
GCK-MODY diabetes associated with protein misfolding, cellular self-association and degradation.
Department of Clinical Medicine, University of Bergen, N-5020 Bergen, Norway.
Biochimica et Biophysica Acta (impact factor:
4.66).
07/2012;
1822(11):1705-15.
DOI:10.1016/j.bbadis.2012.07.005
pp.1705-15
Source: PubMed
- Citations (1)
-
Cited In (0)
-
Article: Generation of N-ethyl-N-nitrosourea (ENU) diabetes models in mice demonstrates genotype-specific action of glucokinase activators.
[show abstract] [hide abstract]
ABSTRACT: We performed genome-wide mutagenesis in C57BL/6J mice using N-ethyl-N-nitrosourea to identify mutations causing high blood glucose early in life and to produce new animal models of diabetes. Of a total of 13 new lines confirmed by heritability testing, we identified two semi-dominant pedigrees with novel missense mutations (Gck(K140E) and Gck(P417R)) in the gene encoding glucokinase (Gck), the mammalian glucose sensor that is mutated in human maturity onset diabetes of the young type 2 and the target of emerging anti-hyperglycemic agents that function as glucokinase activators (GKAs). Diabetes phenotype corresponded with genotype (mild-to-severe: Gck(+/+) < Gck(P417R/+), Gck(K140E)(/+) < Gck(P417R/P417R), Gck(P417R/K140E), and Gck(K140E/K140E)) and with the level of expression of GCK in liver. Each mutant was produced as the recombinant enzyme in Escherichia coli, and analysis of k(cat) and tryptophan fluorescence (I(320/360)) during thermal shift unfolding revealed a correlation between thermostability and the severity of hyperglycemia in the whole animal. Disruption of the glucokinase regulatory protein-binding site (GCK(K140E)), but not the ATP binding cassette (GCK(P417R)), prevented inhibition of enzyme activity by glucokinase regulatory protein and corresponded with reduced responsiveness to the GKA drug. Surprisingly, extracts from liver of diabetic GCK mutants inhibited activity of the recombinant enzyme, a property that was also observed in liver extracts from mice with streptozotocin-induced diabetes. These results indicate a relationship between genotype, phenotype, and GKA efficacy. The integration of forward genetic screening and biochemical profiling opens a pathway for preclinical development of mechanism-based diabetes therapies.Journal of Biological Chemistry 09/2011; 286(45):39560-72. · 4.77 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
>600 different mutations
catalytically 'normal' GCK mutations
cellular dimerization/aggregation
conformational changes
disease mechanism
form dimers
GK)-encoding gene
increased rate
mild fasting hyperglycemia
molecular mechanism(s)
molecular mechanisms
normal/near-normal catalytic properties
protein misfolding
protein quality control machinery
pulse-chase experiments
recombinant pancreatic proteins
SDS resistant
similar properties
subcellular fractionation
Triton X-100 insoluble